The Readout Loud cover image

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

The Readout Loud

00:00

Setbacks for Kobenphi: A Promising Drug Faces Challenges

This chapter explores the disappointing trial results for Bristol-Myers Squibb's schizophrenia drug, Kobenphi, which failed to show significant benefits when added to existing treatments. It also highlights the complexities of psychiatric drug trials and introduces a new biotech startup focused on preemptive medicines.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app